Research

Hormonal

Dulaglutide, subcutaneous semaglutide, and tirzepatide exhibit comparable risks of severe gastrointestinal adverse events (including acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation) in adults with type 2 diabetes.

If you are choosing between dulaglutide, semaglutide, or tirzepatide for type 2 diabetes, do not expect a significant difference in the risk of serious stomach problems (like pancreatitis or bowel obstruction) between them. They all carry a similar, low risk of severe GI events, though mild nausea or diarrhea is common with all. Your choice should likely be based on efficacy (weight loss/glycemic control), cost, and tolerability of mild side effects rather than fear of severe GI complications.

GoodSupportsHIGH confidence
These findings suggest that dulaglutide, semaglutide, and tirzepatide have comparable gastrointestinal safety profiles in adults with T2D.
Salvatore Crisafulli et al. · Annals of Internal Medicine · 2025

Why this rating

Large-scale real-world observational study with propensity score matching (n > 130,000 matched pairs), though not an RCT.

Source

Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes

Salvatore Crisafulli et al. · Annals of Internal Medicine · 2025

DOI 10.7326/annals-25-01724

cohortCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →